Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments_老虎社区_美港股上老虎

Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments

Bloomberg2021-11-05

Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Tanyl
·2021-11-07
Merck is a good buy
回复
2
举报
YTRT
·2021-11-07
Thanks
回复
1
举报
boonk
·2021-11-06
Both are good
回复
点赞
举报
dorbymiao
·2021-11-06
$Moderna, Inc.(MRNA)$stock is crashing down partly because of this?
回复
1
举报
收起
- Stripey:
  Yes. Market is thinking with the pill we don't need vaccines
  2021-11-06
  回复
  举报
sylarspock
·2021-11-06
Good news
回复
点赞
举报
jesslzh
·2021-11-06
Hope it comes true
回复
1
举报
收起
- sylarspock:
  Yeah
  2021-11-06
  回复
  举报
Vanillin
·2021-11-06
Both companies have done well for humanity.
回复
点赞
举报
miaomee
·2021-11-06
Great
回复
1
举报
woonws
·2021-11-05
Useful summary on both drugs
回复
1
举报
收起
- Kave:
  [开心] [开心]
  2021-11-05
  回复
  举报
woonws
·2021-11-05
Useful summary of how both drugs work
回复
1
举报
Tiramisu2020
·2021-11-05
Like
回复
1
举报
Dawang
·2021-11-05
More lives can be saved!
回复
2
举报
Alvin1975
·2021-11-05
Liked!
回复
3
举报
收起
- ponyinvestor:
  Like and leave a comment on my post pls
  2021-11-05
  回复
  举报
- Alvin1975:
  Liked
  2021-11-05
  回复
  举报
cryptous
·2021-11-05
K
回复
2
举报
Bonds
·2021-11-05
Yes the winner is P……
回复
1
举报
Hangen
·2021-11-05
Look like it is a bad news for Merck.
回复
4
举报
收起
- JBT:
  Bad for moderna
  2021-11-05
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1188368870?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-05 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188368870","market":"us","top_or_hot":-1,"title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","media":"Bloomberg","content":"<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">网页链接</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","article_id":"1188368870","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","pubTimestamp":1636122141,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞","MRK":"默沙东"},"translate_title":"辉瑞vs默克：看两种新的Covid药丸治疗方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9,"PFE":0.9},"content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":845353806,"gmtCreate":1636290353798,"gmtModify":1636290354268,"author":{"id":"4087109808120260","authorId":"4087109808120260","name":"Tanyl","avatar":"https://static.tigerbbs.com/174329973340cf0f5b68791ee5b08afd","vip":1,"crmLevel":9,"crmLevelSwitch":0},"htmlText":"Merck is a good buy","listText":"Merck is a good buy","text":"Merck is a good buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845353806","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":845085029,"gmtCreate":1636253080327,"gmtModify":1636253080504,"author":{"id":"4088994282428880","authorId":"4088994282428880","name":"YTRT","avatar":"https://static.tigerbbs.com/344b95c303c752be1a1e529b4f91ae17","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845085029","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":842152827,"gmtCreate":1636157919181,"gmtModify":1636157920142,"author":{"id":"3580955744929134","authorId":"3580955744929134","name":"boonk","avatar":"https://static.tigerbbs.com/6e58310c6a80ddfbcb69e0989cda7858","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Both are good","listText":"Both are good","text":"Both are good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842152827","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":842181295,"gmtCreate":1636155841382,"gmtModify":1636155841466,"author":{"id":"4093220244813210","authorId":"4093220244813210","name":"dorbymiao","avatar":"https://static.tigerbbs.com/36a7b09dc1d7fdc5a2065eaf815a696e","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>stock is crashing down partly because of this?","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>stock is crashing down partly because of this?","text":"$Moderna, Inc.(MRNA)$stock is crashing down partly because of this?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842181295","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6474480,"gmtCreate":1636169329427,"gmtModify":1636169329537,"authorId":4096341081825100,"author":{"id":4096341081825100,"authorId":4096341081825100,"name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":842181295,"type":1,"supId":0,"prevId":0,"content":"Yes. Market is thinking with the pill we don't need vaccines","text":"Yes. Market is thinking with the pill we don't need vaccines","html":"Yes. Market is thinking with the pill we don't need vaccines"}],"langContent":"CN"},{"id":842101485,"gmtCreate":1636152337434,"gmtModify":1636152337982,"author":{"id":"3582677817626222","authorId":"3582677817626222","name":"sylarspock","avatar":"https://static.tigerbbs.com/af2ee7f5466dab8465d661a72c047672","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good news&nbsp;","listText":"Good news&nbsp;","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842101485","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":842317151,"gmtCreate":1636133358716,"gmtModify":1636133449646,"author":{"id":"4099173660726180","authorId":"4099173660726180","name":"jesslzh","avatar":"https://static.tigerbbs.com/4a45f712cd48040341f4e9bf06fe0881","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Hope it comes true","listText":"Hope it comes true","text":"Hope it comes true","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842317151","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6470526,"gmtCreate":1636152330260,"gmtModify":1636152330295,"authorId":3582677817626222,"author":{"id":3582677817626222,"authorId":3582677817626222,"name":"sylarspock","avatar":"https://static.tigerbbs.com/af2ee7f5466dab8465d661a72c047672","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":842317151,"type":1,"supId":0,"prevId":0,"content":"Yeah ","text":"Yeah ","html":"Yeah "}],"langContent":"CN"},{"id":842316348,"gmtCreate":1636132796379,"gmtModify":1636133434775,"author":{"id":"3572310408162611","authorId":"3572310408162611","name":"Vanillin","avatar":"https://static.tigerbbs.com/57da3673038af147111405348d5fa098","vip":1,"crmLevel":7,"crmLevelSwitch":0},"htmlText":"Both companies have done well for humanity.","listText":"Both companies have done well for humanity.","text":"Both companies have done well for humanity.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842316348","repostId":1188368870,"repostType":2,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":842975725,"gmtCreate":1636128896897,"gmtModify":1636128897461,"author":{"id":"3569375896365334","authorId":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842975725","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":842921875,"gmtCreate":1636126383218,"gmtModify":1636126384084,"author":{"id":"3581999478634265","authorId":"3581999478634265","name":"woonws","avatar":"https://static.tigerbbs.com/f26ed1a10ee84ab97229aad191ef3133","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Useful summary on both drugs","listText":"Useful summary on both drugs","text":"Useful summary on both drugs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842921875","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6469124,"gmtCreate":1636127721146,"gmtModify":1636127721243,"authorId":4090112981805970,"author":{"id":4090112981805970,"authorId":4090112981805970,"name":"Kave","avatar":"https://static.tigerbbs.com/7928a22910f1e6651ac7f9dbf8e9c369","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":842921875,"type":1,"supId":0,"prevId":0,"content":"[开心] [开心]","text":"[开心] [开心]","html":"[开心] [开心]"}],"langContent":"CN"},{"id":842923757,"gmtCreate":1636126364830,"gmtModify":1636126365706,"author":{"id":"3581999478634265","authorId":"3581999478634265","name":"woonws","avatar":"https://static.tigerbbs.com/f26ed1a10ee84ab97229aad191ef3133","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Useful summary of how both drugs work","listText":"Useful summary of how both drugs work","text":"Useful summary of how both drugs work","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842923757","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":842986243,"gmtCreate":1636125379032,"gmtModify":1636125379358,"author":{"id":"4089812543711440","authorId":"4089812543711440","name":"Tiramisu2020","avatar":"https://static.tigerbbs.com/c7923aecbb67682b46eed9d583bc08c3","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842986243","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":842913681,"gmtCreate":1636124622265,"gmtModify":1636124624151,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"More lives can be saved!","listText":"More lives can be saved!","text":"More lives can be saved!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842913681","repostId":1188368870,"repostType":2,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":842997170,"gmtCreate":1636123889858,"gmtModify":1636123895337,"author":{"id":"3573788625955643","authorId":"3573788625955643","name":"Alvin1975","avatar":"https://static.tigerbbs.com/beba0668af2d109b87221754e75935b3","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Liked!","listText":"Liked!","text":"Liked!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/842997170","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6468319,"gmtCreate":1636124006442,"gmtModify":1636124006548,"authorId":3575443999456708,"author":{"id":3575443999456708,"authorId":3575443999456708,"name":"ponyinvestor","avatar":"https://static.tigerbbs.com/138d1ebc8820019726a687f0ffe45994","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":842997170,"type":1,"supId":0,"prevId":0,"content":"Like and leave a comment on my post pls","text":"Like and leave a comment on my post pls","html":"Like and leave a comment on my post pls"},{"id":6468297,"gmtCreate":1636123898702,"gmtModify":1636123898791,"authorId":3573788625955643,"author":{"id":3573788625955643,"authorId":3573788625955643,"name":"Alvin1975","avatar":"https://static.tigerbbs.com/beba0668af2d109b87221754e75935b3","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":842997170,"type":1,"supId":0,"prevId":0,"content":"Liked","text":"Liked","html":"Liked"}],"langContent":"CN"},{"id":842077689,"gmtCreate":1636122893391,"gmtModify":1636122893617,"author":{"id":"3581640085724727","authorId":"3581640085724727","name":"cryptous","avatar":"https://static.tigerbbs.com/c66c79b1c0f576bf4133fe7ceb3916ae","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842077689","repostId":1188368870,"repostType":4,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":842075095,"gmtCreate":1636122799175,"gmtModify":1636122799552,"author":{"id":"3582366643541036","authorId":"3582366643541036","name":"Bonds","avatar":"https://static.tigerbbs.com/7927febac32666ca13d21b532f0ff6f6","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Yes the winner is P……","listText":"Yes the winner is P……","text":"Yes the winner is P……","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842075095","repostId":1188368870,"repostType":2,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":842046216,"gmtCreate":1636122380372,"gmtModify":1636122380593,"author":{"id":"4087724962016220","authorId":"4087724962016220","name":"Hangen","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Look like it is a bad news for Merck.","listText":"Look like it is a bad news for Merck.","text":"Look like it is a bad news for Merck.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842046216","repostId":1188368870,"repostType":2,"repost":{"id":"1188368870","pubTimestamp":1636122141,"share":"https://www.laohu8.com/m/news/1188368870?lang=&edition=full","pubTime":"2021-11-05 22:22","market":"us","language":"en","title":"Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1188368870","media":"Bloomberg","summary":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge t","content":"<p>Pfizer Inc.&nbsp;released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from&nbsp;Merck &amp; Co.&nbsp;and&nbsp;Ridgeback Biotherapeutics LP&nbsp;that’s already been cleared for use in the U.K.</p>\n<p>While the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.</p>\n<p>Here are a few facts that we can put side-by-side until the data are analyzed further:</p>\n<p><img src=\"https://static.tigerbbs.com/12b6a26c0eef9971bb0ec9371bb3a756\" tg-width=\"969\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vs. Merck: A Look at the Two New Covid Pill Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vs. Merck: A Look at the Two New Covid Pill Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-vs-merck-a-look-at-the-two-new-covid-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188368870","content_text":"Pfizer Inc. released data on its experimental Covid pill Friday that suggest a potential challenge to molnupiravir, the drug from Merck & Co. and Ridgeback Biotherapeutics LP that’s already been cleared for use in the U.K.\nWhile the Pfizer pill showed an 89% reduction in hospitalization or death in high-risk Covid-19-infected individuals, and Merck’s showed a 50% reduction, “we can’t yet compare the two until the risk profile of the patients is clearer,” according to Bloomberg Intelligence analyst Sam Fazeli.\nHere are a few facts that we can put side-by-side until the data are analyzed further:","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6467953,"gmtCreate":1636122467670,"gmtModify":1636122467702,"authorId":3581751165798598,"author":{"id":3581751165798598,"authorId":3581751165798598,"name":"JBT","avatar":"https://static.tigerbbs.com/1ffd34e99f27855f8ef139a4bdb4503f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":842046216,"type":1,"supId":0,"prevId":0,"content":"Bad for <u>moderna</u>","text":"Bad for <u>moderna</u>","html":"Bad for <u>moderna</u>"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":90,"commentSize":16,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}